Steroid 21 Hydroxylase Deficiency Congenital Adrenal Hyperplasia

Endocrinology and Metabolism Clinics of North America

Volumn 38, Issue 4, 2009, Pages 699-718

  Nimkarn, Saroj ^a   Lin Su, Karen ^a   New, Maria I ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

21 hydroxylase; 21 OHD; Adrenal steroid; Congenital adrenal hyperplasia

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; FLUDROCORTISONE; GLUCOCORTICOID; HYDROCORTISONE; HYDROXYPROGESTERONE;

ADULTHOOD; BONE DENSITY; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONGENITAL ADRENAL HYPERPLASIA; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE CLASSIFICATION; DRUG DOSE INCREASE; EDEMA; FEMALE FERTILITY; GENE MUTATION; GENITAL MALFORMATION; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; MOLECULAR GENETICS; NONHUMAN; PATHOPHYSIOLOGY; PRENATAL CARE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; STEROID 21 MONOOXYGENASE DEFICIENCY; STRIA; UROLOGIC SURGERY; WEIGHT GAIN;

ADRENAL HYPERPLASIA, CONGENITAL; ADULT; CHILD; CONTINUITY OF PATIENT CARE; FEMALE; FERTILITY; HUMANS; MODELS, BIOLOGICAL; PREGNANCY; PREGNANCY COMPLICATIONS; STEROID 21-HYDROXYLASE;

EID: 70449934276     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2009.08.001     Document Type: Review

References (114)

1. Pang S., and Clark A. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: newborn screening and its relationship to the diagnosis and treatment of the disorder. Screening 2 (1993) 105-139
2. Therrell B.J., Berenbaum S., Manter-Kapanke V., et al. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 101 (1998) 583-590
3. Balsamo A., Cacciari E., Piazzi S., et al. Congenital adrenal hyperplasia: neonatal mass screening compared with clinical diagnosis only in the Emilia-Romagna region of Italy, 1980-1995. Pediatrics 98 (1996) 362-367
4. Speiser P.W., Dupont B., Rubinstein P., et al. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet 37 (1985) 650-667
5. Sherman S.L., Aston C.E., Morton N.E., et al. A segregation and linkage study of classical and nonclassical 21-hydroxylase deficiency. Am J Hum Genet 42 (1988) 830-838
6. Ganong W. The central nervous system and the synthesis and release of adrenocorticotrophic hormone. In: Nalbandov A. (Ed). Advances in neuroendocrinology (1963), University of Illinois Press, Urbana 92
7. Guillemin R., and Schally A. Recent advances in the chemistry of neuroendocrine mediators originating in the central nervous system. In: Nalbandov A. (Ed). Advances in neuroendocrinology (1963), University of Illinois Press, Urbana 314
8. Goto M., Piper Hanley K., Marcos J., et al. In humans, early cortisol biosynthesis provides a mechanism to safeguard female sexual development. J Clin Invest 116 (2006) 953-960
9. Prader A., and Gurtner H.P. [The syndrome of male pseudohermaphrodism in congenital adrenocortical hyperplasia without overproduction of androgens (adrenal male pseudohermaphrodism)]. Helv Paediatr Acta 10 (1955) 397-412
10. Eugster E.A., Dimeglio L.A., Wright J.C., et al. Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis. J Pediatr 138 (2001) 26-32
11. Muirhead S., Sellers E.A., and Guyda H. Indicators of adult height outcome in classical 21-hydroxylase deficiency congenital adrenal hyperplasia. J Pediatr 141 (2002) 247-252
12. Brunelli V., Russo G., Bertelloni S., et al. Final height in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: the Italian experience. J Pediatr Endocrinol Metab 16 Suppl 2 (2003) 277-283
13. Lin-Su K., Vogiatzi M.G., Marshall I., et al. Treatment with growth hormone and luteinizing hormone releasing hormone analog improves final adult height in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 90 (2005) 3318-3325
14. Quintos J.B., Vogiatzi M.G., Harbison M.D., et al. Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 86 (2001) 1511-1517
15. Jones H., and Verkauf B. Congenital adrenal hyperplasia: age at menarche and related events at puberty. Am J Obstet Gynecol 109 (1971) 292
16. Ghali I., David M., and David L. Linear growth and pubertal development in treated congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 6 (1977) 425-436
17. Trinh L, Nimkarn S, Obeid J, et al. Growth and pubertal characteristics in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. ENDO 2006 The Endocrine Society's 88th Annual Meeting. Boston, Massachusetts, June 24-27, 2006. p. 368.
18. Klingensmith G., Garcia S., Jones H., et al. Glucocorticoid treatment of girls with congenital adrenal hyperplasia: effects on height, sexual maturation, and fertility. J Pediatr 90 (1977) 996-1004
19. Barnes R.B., Rosenfield R.L., Ehrmann D.A., et al. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab 79 (1994) 1328-1333
20. Long D.N., Wisniewski A.B., and Migeon C.J. Gender role across development in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Pediatr Endocrinol Metab 17 (2004) 1367-1373
21. Meyer-Bahlburg H.F., Dolezal C., Baker S.W., et al. Sexual orientation in women with classical or non-classical congenital adrenal hyperplasia as a function of degree of prenatal androgen excess. Arch Sex Behav 37 (2008) 85-99
22. Hines M., Brook C., and Conway G.S. Androgen and psychosexual development: core gender identity, sexual orientation and recalled childhood gender role behavior in women and men with congenital adrenal hyperplasia (CAH). J Sex Res 41 (2004) 75-81
23. Mulaikal R.M., Migeon C.J., and Rock J.A. Fertility rates in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med 316 (1987) 178-182
24. Premawardhana L., Hughes I., Read G., et al. Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience. Clin Endocrinol (Oxf) 46 (1997) 327-332
25. Prader A., Zachmann M., and Illig R. Normal spermatogenesis in adult males with congenital adrenal hyperplasia after discontinuation of therapy. In: Lee P., Platnick L., Kowarski A., et al. (Eds). Congenital adrenal hyperplasia (1977), University Park Press, Baltimore (MD) 397
26. Stewart J. A fertile male with untreated congenital adrenal hyperplasia. Acta Endocrinol Suppl 51 (1960) 661
27. Urban M., Lee P., and Migeon C. Adult height and fertility in men with congenital virilizing adrenal hyperplasia. N Engl J Med 299 (1978) 1392
28. Cabrera M., Vogiatzi M., and New M. Long term outcome in adult males with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 86 (2001) 3070-3080
29. Sugino Y., Usui T., Okubo K., et al. Genotyping of congenital adrenal hyperplasia due to 21-hydroxylase deficiency presenting as male infertility: case report and literature review. J Assist Reprod Genet 23 (2006) 377-380
30. Bonaccorsi A., Adler I., and Figueiredo J. Male infertility due to congenital adrenal hyperplasia: testicular biopsy findings, hormonal evaluation, and therapeutic results in three patients. Fertil Steril 47 (1987) 664-670
31. Claahsen-van der Grinten H.L., Sweep F.C., Blickman J.G., et al. Prevalence of testicular adrenal rest tumours in male children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur J Endocrinol 157 (2007) 339-344
32. Molitor J., Chertow B., and Fariss B. Long-term follow-up of a patient with congenital adrenal hyperplasia and failure of testicular development. Fertil Steril 24 (1973) 319
33. Blumberg-Tick J., Boudou P., Nahoul K., et al. Testicular tumors in congenital adrenal hyperplasia: steroid measurements from adrenal and spermatic veins. J Clin Endocrinol Metab 73 (1991) 1129-1133
34. Claahsen-van der Grinten H.L., Otten B.J., Hermus A.R., et al. Testicular adrenal rest tumors in patients with congenital adrenal hyperplasia can cause severe testicular damage. Fertil Steril 89 (2008) 597-601
35. Schoen E., DiRaimondo V., and Dominguez O. Bilateral testicular tumors complicating congenital adrenocortical hyperplasia. J Clin Endocrinol Metab 21 (1961) 518
36. Miller E., and Murray H. Congenital adrenocortical hyperplasia: case previously reported as "bilateral interstitial cell tumor of the testicle". J Clin Endocrinol Metab 22 (1962) 655
37. Glenn J., and Boyce W. Adrenogenitalism with testicular adrenal rests simulating interstitial cell tumor. J Urol 89 (1963) 456
38. Srikanth M., West B., Ishitani M., et al. Benign testicular tumors in children with congenital adrenal hyperplasia. J Pediatr Surg 27 (1992) 639-641
39. Rutgers J., Young R., and Scully R. The testicular "tumor" of the adrenogenital syndrome. A report of six cases and review of the literature on testicular masses in patients with adrenocortical disorders. Am J Surg Pathol 12 (1988) 503-513
40. Wilkins L., Crigler J., Silverman S., et al. Further studies on the treatment of congenital adrenal hyperplasia with cortisone. II. The effects of cortisone on sexual and somatic development, with a hypothesis concerning the mechanism of feminization. J Clin Endocrinol Metab 12 (1952) 277
41. Klein R. Evidence for and evidence against the existence of a salt-losing hormone. J Pediatr 57 (1960) 452
42. Kowarski A., Finkelstein J.W., Spaulding J.S., et al. Aldosterone secretion rate in congenital adrenal hyperplasia. A discussion of the theories on the pathogenesis of the salt-losing form of the syndrome. J Clin Invest 44 (1965) 1505-1513
43. Kuhnle U., Land M., and Ulick S. Evidence for the secretion of an antimineralocorticoid in congenital adrenal hyperplasia. J Clin Endocrinol Metab 62 (1986) 934-940
44. Merke D., Chrousos G., Eisenhofer G., et al. Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med 343 (2000) 1362-1368
45. Stoner E., Dimartino-Nardi J., Kuhnle U., et al. Is salt-wasting in congenital adrenal hyperplasia due to the same gene as the fasciculata defect?. Clin Endocrinol (Oxf) 24 (1986) 9-20
46. Luetscher J.A. Studies of aldosterone in relation to water and electrolyte balance in man. Recent Prog Horm Res 12 (1956) 175
47. Speiser P.W., Agdere L., Ueshiba H., et al. Aldosterone synthesis in salt-wasting congenital adrenal hyperplasia with complete absence of adrenal 21-hydroxylase. N Engl J Med 324 (1991) 145-149
48. Nimkarn S., and New M.I. Prenatal diagnosis and treatment of congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Nat Clin Pract Endocrinol Metab 3 (2007) 405-413
49. New M.I. Nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab 91 (2006) 4205-4214
50. New M.I. Extensive clinical experience: nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab 91 (2006) 4205-4214
51. Kashimada K., Ono M., Onishi T., et al. Clinical course of patients with nonclassical 21-hydroxylase deficiency (21-OHD) diagnosed in infancy and childhood. Endocr J 55 (2008) 397-404
52. Fanta M., Cibula D., and Vrbikova J. Prevalence of nonclassic adrenal hyperplasia (NCAH) in hyperandrogenic women. Gynecol Endocrinol 24 (2008) 154-157
53. Escobar-Morreale H.F., Sanchon R., and San Millan J.L. A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs. J Clin Endocrinol Metab 93 (2008) 527-533
54. Claahsen-van der Grinten H.L., Otten B.J., Sweep F.C., et al. Repeated successful induction of fertility after replacing hydrocortisone with dexamethasone in a patient with congenital adrenal hyperplasia and testicular adrenal rest tumors. Fertil Steril 88 (2007) 705 e5-8
55. Jaaskelainen J., Tiitinen A., and Voutilainen R. Sexual function and fertility in adult females and males with congenital adrenal hyperplasia. Horm Res 56 (2001) 73-80
56. Clayton P.E., Miller W.L., Oberfield S.E., et al. Consensus statement on 21-hydroxylase deficiency from the European Society for Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society. Horm Res 58 (2002) 188-195
57. Mokshagundam S., and Surks M. Congenital adrenal hyperplasia diagnosed in a man during workup for bilateral adrenal masses. Arch Intern Med 153 (1993) 1389-1391
58. Jaresch S., Kornely E., Kley H., et al. Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia. J Clin Endocrinol Metab 74 (1992) 685-689
59. Wilson R.C., Mercado A.B., Cheng K.C., et al. Steroid 21-hydroxylase deficiency: genotype may not predict phenotype. J Clin Endocrinol Metab 80 (1995) 2322-2329
60. Dupont B., Oberfield S.E., Smithwick E.M., et al. Close genetic linkage between HLA and congenital adrenal hyperplasia (21-hydroxylase deficiency). Lancet 2 (1977) 1309-1312
61. Nebert D.W., Nelson D.R., and Coon M.J. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol 10 (1991) 1-14
62. White P.C., New M.I., and Dupont B. Structure of the human steroid 21-hydroxylase genes. Proc Natl Acad Sci U S A 83 (1986) 5111-5115
63. Stenson P.D., Ball E.V., Mort M., et al. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 21 (2003) 577-581
64. Tusie-Luna M.T., Speiser P.W., Dumic M., et al. A mutation (Pro-30 to Leu) in CYP21 represents a potential nonclassic steroid 21-hydroxylase deficiency allele. Mol Endocrinol 5 (1991) 685-692
65. Speiser P.W., New M.I., and White P.C. Molecular genetic analysis of nonclassic steroid 21-hydroxylase deficiency associated with HLA-B14, DR1. N Engl J Med 319 (1988) 19-23
66. Helmberg A., Tusie-Luna M., Tabarelli M., et al. R339H and P453S: CYP21 mutations associated with nonclassic steroid 21-hydroxylase deficiency that are not apparent gene conversions. Mol Endocrinol 6 (1992) 1318-1322
67. Owerbach D., Sherman L., Ballard A.L., et al. Pro-453 to Ser mutation in CYP21 is associated with nonclassic steroid 21-hydroxylase deficiency. Mol Endocrinol 6 (1992) 1211-1215
68. White P.C., New M.I., and Dupont B. HLA-linked congenital adrenal hyperplasia results from a defective gene encoding a cytochrome P-450 specific for steroid 21-hydroxylation. Proc Natl Acad Sci U S A 81 (1984) 7505-7509
69. Higashi Y., Tanae A., Inoue H., et al. Aberrant splicing and missense mutations cause steroid 21-hydroxylase [P-450(C21)] deficiency in humans: possible gene conversion products. Proc Natl Acad Sci U S A 85 (1988) 7486-7490
70. White P.C., Tusie-Luna M.T., New M.I., et al. Mutations in steroid 21-hydroxylase (CYP21). Hum Mutat 3 (1994) 373-378
71. Tusie-Luna M., Traktman P., and White P.C. Determination of functional effects of mutations in the steroid 21-hydroxylase gene (CYP21) using recombinant vaccinia virus. J Biol Chem 265 (1990) 20916-20922
72. Amor M., Parker K.L., Globerman H., et al. Mutation in the CYP21B gene (Ile-172-Asn) causes steroid 21-hydroxylase deficiency. Proc Natl Acad Sci U S A 85 (1988) 1600-1607
73. Globerman H., Amor M., Parker K.L., et al. Nonsense mutation causing steroid 21-hydroxylase deficiency. J Clin Invest 82 (1988) 139-144
74. Chiou S.H., Hu M.C., and Chung B.C. A missense mutation at Ile172-Asn or Arg356-Trp causes steroid 21-hydroxylase deficiency. J Biol Chem 265 (1990) 3549-3552
75. Wedell A., and Luthman H. Steroid 21-hydroxylase (P450c21): a new allele and spread of mutations through the pseudogene. Hum Genet 91 (1993) 236-240
76. Speiser P.W., Dupont J., Zhu D., et al. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 90 (1992) 584-595
77. Wedell A., Ritzen E.M., Haglund-Stengler B., et al. Steroid 21-hydroxylase deficiency: three additional mutated alleles and establishment of phenotype-genotype relationships of common mutations. Proc Natl Acad Sci U S A 89 (1992) 7232-7236
78. Krone N., Braun A., Roscher A., et al. Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. J Clin Endocrinol Metab 85 (2000) p1059-p1065
79. Chemaitilly W., Betensky B., Marshal I., et al. Case report: the natural history and genotype-phenotype nonconcordance of HLA identical siblings with the same mutations of the 21-hydroxylase gene. J Pediatr Endocrinol Metab 18 (2005) 143-154
80. Rohana A.G., Ming W., Norlela S., et al. Functioning adrenal adenoma in association with congenital adrenal hyperplasia. Med J Malaysia 62 (2007) 158-159
81. Jansen M., Wit J.M., and van den Brande J.L. Reinstitution of mineralocorticoid therapy in congenital adrenal hyperplasia. Effects on control and growth. Acta Paediatr Scand 70 (1981) 229-233
82. Forest M.G., and Dorr H.G. Prenatal therapy in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: retrospective follow-up study of 253 treated pregnancies in 215 families. Endocrinologist 13 (2003) 252-259
83. Schachter S.C. Handedness in women with intrauterine exposure to diethystilbestrol. Neuropsychologia 32 (1994) 619-623
84. Schnitzer J., and Donahoe P. Surgical treatment of congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 30 (2001) 137-154
85. Crouch N.S., Liao L.M., Woodhouse C.R., et al. Sexual function and genital sensitivity following feminizing genitoplasty for congenital adrenal hyperplasia. J Urol 179 (2008) 634-638 Epub 2007 Dec 21
86. Gastaud F., Bouvattier C., Duranteau L., et al. Impaired sexual and reproductive outcomes in women with classical forms of congenital adrenal hyperplasia. Clin Endocrinol Metab 92 (2007) 1391-1396
87. Nordenskjold A., Holmdahl G., Frisen L., et al. Type of mutation and surgical procedure affect long-term quality of life for women with congenital adrenal hyperplasia. J Clin Endocrinol Metab 93 (2008) 380-386
88. Mazziotti G., Giustina A., Canalis E., et al. Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects. Arq Bras Endocrinol Metabol 51 (2007) 1404-1412
89. Falhammar H., Filipsson H., Holmdahl G., et al. Fractures and bone mineral density in adult women with 21-hydroxylase deficiency. J Clin Endocrinol Metab 92 (2007) 4643-4649
90. King J.A., Wisniewski A.B., Bankowski B.J., et al. Long-term corticosteroid replacement and bone mineral density in adult women with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab 91 (2006) 865-869
91. Stikkelbroeck N., Oyen W., van der Wilt G.J., et al. Normal bone mineral density and lean body mass, but increased fat mass, in young adult patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 88 (2003) 1036-1042
92. Christiansen P., Molgaard C., and Muller J. Normal bone mineral content in young adults with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res 61 (2004) 133-136
93. Cornean R.E., Hindmarsh P.C., and Brook C.G. Obesity in 21-hydroxylase deficient patients. Arch Dis Child 78 (1998) 261-263
94. Charmandari E., and Chrousos G.P. Metabolic syndrome manifestations in classic congenital adrenal hyperplasia: do they predispose to atherosclerotic cardiovascular disease and secondary polycystic ovary syndrome?. Ann N Y Acad Sci 1083 (2006) 37-53
95. Volkl T.M., Simm D., Beier C., et al. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 117 (2006) e98-e105
96. Speiser P.W., Serrat J., New M.I., et al. Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 75 (1992) 1421-1424
97. Charmandari E., Weise M., Bornstein S., et al. Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance: potential clinical implications. J Clin Endocrinol Metab 87 (2002) 2114-2120
98. Sartorato P., Zulian E., Benedini S., et al. Cardiovascular risk factors and ultrasound evaluation of intima-media thickness at common carotids, carotid bulbs, and femoral and abdominal aorta arteries in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 92 (2007) 1015-1018
99. Falhammar H., Filipsson H., Holmdahl G., et al. Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 92 (2007) 110-116
100. Roche E.F., Charmandari E., Dattani M.T., et al. Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): a preliminary report. Clin Endocrinol (Oxf) 58 (2003) 589-596
101. Weise M., Drinkard B., Mehlinger S.L., et al. Stress dose of hydrocortisone is not beneficial in patients with classic congenital adrenal hyperplasia undergoing short-term, high-intensity exercise. J Clin Endocrinol Metab 89 (2004) 3679-3684
102. Green-Golan L., Yates C., Drinkard B., et al. Patients with classic congenital adrenal hyperplasia have decreased epinephrine reserve and defective glycemic control during prolonged moderate-intensity exercise. J Clin Endocrinol Metab 92 (2007) 3019-3024
103. Burton P.J., and Waddell B.J. Dual function of 11beta-hydroxysteroid dehydrogenase in placenta: modulating placental glucocorticoid passage and local steroid action. Biol Reprod 60 (1999) 234-240
104. Rennick G.J. Use of systemic glucocorticosteroids in pregnancy: be alert but not alarmed. Australas J Dermatol 47 (2006) 34-36
105. Carlson A.D., Obeid J.S., Kanellopoulou N., et al. Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency. In: New M.I. (Ed). Diagnosis and treatment of the unborn child (1999), Idelson-Gnocchi Ltd. Publisher, Reddick (FL) 75-84
106. New M., Carlson A., Obeid J., et al. Update: Prenatal diagnosis for congenital adrenal hyperplasia in 595 pregnancies. Endocrinologist 13 (2003) 233-239
107. Goldman A., Sharpior B., and Katsumata M. Human foetal palatal corticoid receptors and teratogens for cleft palate. Nature 272 (1978) 464-466
108. Nimkarn S., and New M.I. Prenatal diagnosis and treatment of congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Nat Clin Pract Endocrinol Metab 3 (2007) 405-413
109. Pang S., Clark A.T., Freeman L.O., et al. Maternal side-effects of prenatal dexamethasone therapy for fetal congenital adrenal hyperplasia. J Clin Endocrinol Metab 76 (1992) 249-253
110. Lajic S., Wedell A., Bui T., et al. Long-term somatic follow-up of prenatally treated children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 83 (1998) 3872-3880
111. Meyer-Bahlburg H.F., Dolezal C., Baker S.W., et al. Cognitive and motor development of children with and without congenital adrenal hyperplasia after early-prenatal dexamethasone. J Clin Endocrinol Metab 89 (2004) 610-614
112. Hirvikoski T., Nordenstrom A., Lindholm T., et al. Cognitive functions in children at risk for congenital adrenal hyperplasia treated prenatally with dexamethasone. J Clin Endocrinol Metab 92 (2007) 542-548
113. Hirvikoski T., Nordenstrom A., Lindholm T., et al. Long-term follow-up of prenatally treated children at risk for congenital adrenal hyperplasia: does dexamethasone cause behavioural problems?. Eur J Endocrinol 159 (2008) 309-316
114. Kruse B., Riepe F.G., Krone N., et al. Congenital adrenal hyperplasia-how to improve the transition from adolescence to adult life. Exp Clin Endocrinol Diabetes 112 (2004) 343-355